Guardant Health Stock Rallies but Analysts Flag Cash Burn and Debt Risks

Guardant Health (GH) shares have climbed 22.7% over the past six months to $129.08, outpacing the S&P 500 by 11.7 percentage points as of June 1, 2026. Despite the rally, an investment analysis urged caution, citing the company’s persistent cash consumption and high leverage. The medical diagnostics firm posted a negative free cash flow margin averaging 47.1% over the last five years, burning $47.12 for every $100 in revenue. It reported a $221.2 million EBITDA loss in the trailing 12 months, while its $1.83 billion in debt exceeds $1.10 billion in cash, raising liquidity concerns. With just $1.08 billion in annual revenue, the company lacks the scale to compete effectively in its capital-intensive industry, the report noted. The stock trades at a forward price-to-sales ratio of 12.6 times, but analysts warned the risk of permanent capital loss is significant if operations do not improve.